Increased immunosuppression, not anticoagulation, extends cardiac xenograft survival

Transplantation

Volumn 82, Issue 12, 2006, Pages 1787-1791

  Byrne, Guerard W ^a   Davies, William R ^a   Oi, Keiji ^a   Rao, Vinay P ^a   Teotia, Sumeet S ^a   Ricci, David ^a   Tazelaar, Henry D ^a   Walker, Randall C ^a   Logan, John S ^a   McGregor, Christopher G A ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

Anticoagulation; Immunosuppression; Xenotransplantation

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA GALACTOSIDASE; CD20 ANTIBODY; CEFEPIME; CLOPIDOGREL; CYCLOPHOSPHAMIDE; ENOXAPARIN; FIBRIN; POLYMER; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VANCOMYCIN; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULANT THERAPY; ANTICOAGULATION; BABOON; CARDIAC GRAFT REJECTION; CELL DEATH; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MEGADOSE; FIBRIN DEPOSITION; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART GRAFT; HEART MUSCLE CELL; HEART TRANSPLANTATION; HISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MAINTENANCE THERAPY; MICROANGIOPATHY; NONHUMAN; PRIORITY JOURNAL; SPLENECTOMY; STATISTICAL ANALYSIS; SWINE; THROMBOCYTE COUNT; THROMBOSIS; TRANSGENIC ANIMAL; TRANSGENIC PIG; TREATMENT DURATION; VASCULAR NECROSIS; XENOGRAFT;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; ENOXAPARIN; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; PAPIO; SPLENECTOMY; SWINE; THROMBOSIS; TRANSPLANTATION, HETEROLOGOUS;

EID: 33845939353     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000251387.40499.0f     Document Type: Conference Paper

References (23)

1. Palmetshofer A, Galili U, Dalmasso AP, et al. a-galactosyl epitope-mediated activation of porcine aortic endothelial cells: Type I Activation. Transplantation 1998; 65(6): 844.
2. Palmetshofer A, Galili U, Dalmasso AP, et al. a-galactosyl epitope-mediated activation of porcine aortic endothelial cells: Type II Activation. Transplantation 1998; 65(7): 971.
3. Xu H, Yin D, Naziruddin B, et al. The in vitro and in vivo effects of anti-galactose antibodies on endothelial cell activation and xenograft rejection. J Immunol 2003; 170(3): 1531.
4. Gollackner B, Goh SK, Qawi I, et al. Acute vascular rejection of xenografts: roles of natural and elicited xenoreactive antibodies in activation of vascular endothelial cells and induction of procoagulant activity. Transplantation 2004; 77(11): 1735.
5. Platt JL. A perspective on xenograft rejection and accommodation. Immunol Rev 1994; 141: 127.
6. Lin SS, Weidner BC, Byrne GW, et al. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998; 101(8): 1745.
7. Williams JM, Holzknecht ZE, Plummer TB, et al. Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation. Transplantation 2004; 78(10): 1471.
8. Knosalla C, Gollackner B, Buhler L, et al. Correlation of biochemical and hematological changes with graft failure following pig heart and kidney transplantation in baboons. Am J Transplant 2003; 3(12): 1510.
9. Siegel JB, Grey ST, Lesnikoski BA, et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64(6): 888.
10. Kopp CW, Siegel JB, Hancock WW, et al. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation 1997; 63(5): 749.
11. Mazzucato M, DeMarco L, Pradella P, et al. Porcine von Willebrand factor binding to human platelet GPIb induces transmembrane calcium influx. Thromb Haemost 1996; 75(4): 655.
12. Pareti FI, Mazzucato M, Bottini E, Mannucci PM. Interaction of porcine von Willebrand factor with the platelet glycoproteins Ib and IIb/IIIa complex. Br J Haematol 1992; 82: 81.
13. Schirmer JM, Fass DN, Byrne GW, et al. Effective antiplatelet therapy does not prolong transgenic pig to baboon cardiac xenograft survival. Xenotransplantation 2004; 11(5): 436.
14. Byrne GW, Schirmer JM, Fass DN, et al. Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. Am J Transplant 2005; 5(5): 1011.
15. McGregor CGA, Davies WR, Oi K, et al. Cardiac xenotransplantation: Recent preclinical progress with 3-month median survival. J Thorac Cardiovasc Surg 2005; 130(3): 844.
16. McGregor CGA, Teotia SS, Byrne GW, et al. Cardiac xenotransplantation: Progress toward the clinic. Transplantation 2004; 78: 1569.
17. Teotia SS, Walker RC, Schirmer JM, et al. Successful control of early bacterial and fungal infections in a preclinical cardiac xenotransplantation model that achieves prolonged survival. Xenotransplantation 2005; 12: 127.
18. Cowan PJ, Aminian A, Barlow H, et al. Protective effects of recombinant human antithrombin III in pig-to-primate renal xenotransplantation. Am J Transplant 2002; 2(6): 520.
19. Cowan PJ, Aminian A, Barlow H, et al. Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons. Transplantation 2000; 69(12): 2504.
20. Alwayn IPJ, Byhler L, Appel JZ, III, et al. Mechanisms of thrombotic microangiopathy following xenogeneic hematopoietic progenitor cell transplantation. Transplantation 2001; 71(11): 1601.
21. Kuwaki K, Knosalla C, Dor FJMF, et al. Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen. Am J Transplant 2004; 4(3): 363.
22. Cozzi E, Simioni P, Boldrin M, et al. Effects of long-term administration of high-dose recombinant human antithrombin in immunosuppressed primate recipients of porcine xenografts. Transplantation 2005; 80(10): 1501.
23. Chen D, Weber M, McVey JH, et al. Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant 2004; 4(12): 1958.